CN107106582A - Reduce offspring's anxiety - Google Patents
Reduce offspring's anxiety Download PDFInfo
- Publication number
- CN107106582A CN107106582A CN201580061897.1A CN201580061897A CN107106582A CN 107106582 A CN107106582 A CN 107106582A CN 201580061897 A CN201580061897 A CN 201580061897A CN 107106582 A CN107106582 A CN 107106582A
- Authority
- CN
- China
- Prior art keywords
- oligosaccharides
- purposes
- stodgy
- baby
- anxiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 16
- 230000036506 anxiety Effects 0.000 title claims abstract description 16
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 97
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 76
- 239000000203 mixture Substances 0.000 claims description 16
- 230000006651 lactation Effects 0.000 claims description 7
- 210000000481 breast Anatomy 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 235000008935 nutritious Nutrition 0.000 claims description 2
- 238000000968 medical method and process Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 6
- 235000020256 human milk Nutrition 0.000 abstract description 5
- 210000004251 human milk Anatomy 0.000 abstract description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 36
- 238000000034 method Methods 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 235000005911 diet Nutrition 0.000 description 15
- 230000037213 diet Effects 0.000 description 15
- -1 glucose oligosaccharide Chemical class 0.000 description 15
- 230000035611 feeding Effects 0.000 description 14
- 229920001277 pectin Polymers 0.000 description 12
- 239000001814 pectin Substances 0.000 description 11
- 235000010987 pectin Nutrition 0.000 description 11
- 239000002253 acid Substances 0.000 description 9
- 229920001202 Inulin Polymers 0.000 description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 7
- 229940029339 inulin Drugs 0.000 description 7
- 235000013406 prebiotics Nutrition 0.000 description 5
- 235000020940 control diet Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000007529 anxiety like behavior Effects 0.000 description 3
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 2
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 1
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000006198 methoxylation reaction Methods 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Reduction receives come the anxiety of the baby of the breast milk for the mother for taking in stodgy oligosaccharides that controls oneself.
Description
Technical field
The present invention relates to the nutrition of women breast-feeding their children or nutritional supplement arts, it is born especially for the offspring of pregnant woman at it
The nutrition of health benefits is provided afterwards.
Background technology
Life start for stress the phase, from baby due, its can exposed to can influence baby psychological condition it is each
In the factor for planting various kinds.It is anticipated that neonatal mother can do the anything of its baby's feeling way of actively impact.
Have an impact as mother has become increasingly aware of diet to the quality of breast milk, mother also more and more pleased breast-feeding its
Baby, to become increasingly dependent on the nutritional support by beneficial effect is converted into its baby.
The content of the invention
Searching can help to as the nutritional support of ursing mother or breast-feeding mothers with the factor of its baby of actively impact,
The present inventor it is existing surprisingly it has been found that, by applying prebiotics to ursing mother, the anxiety for revealing reduction is represented thereafter.This is in mouse
It is proven in model by following：When offspring is only supplemented with the diet of prebiotics by its mother's breast-feeding and mother's intake
In the case of, compared to the offspring of mother's breast-feeding of the control diet by taking in no prebiotics, by after life early stage
The cry that generation sends tails off.
Embodiment
Therefore, the present invention relates to apply stodgy oligosaccharides by the ursing mother to baby to reduce breast-feeding baby
The method of the anxiety of youngster.
In one embodiment of the invention, the method for reduction anxiety is non-medical procedures.
The invention further relates to stodgy oligosaccharides in the composition for preparing the anxiety for being used for reducing breast feeding babies
Purposes, wherein the composition comprising stodgy oligosaccharides to be applied to the ursing mother of baby.
The invention further relates to reduce breast-feeding for applying stodgy oligosaccharides by the ursing mother to baby
The stodgy oligosaccharides of the anxiety of baby.
Stodgy oligosaccharides
The method or purposes of the present invention includes the administration of stodgy oligosaccharides.Being difficult in the method or purposes of the present invention
The oligosaccharides of digestion preferably (i) acts on indigestion in intestines by sour or digestive ferment present in people's upper digestive tract (small intestine and stomach)
Or be only partly digested and (ii) is fermented by people's gut flora, organic acid can be preferably fermented into, lactic acid, butyric acid is preferably fermented into
Ester, propionic ester and/or acetic acid esters.For example, sucrose, lactose, maltose and maltodextrin are considered as digestible.
Preferably, in the method or purposes of the present invention, the DP of stodgy oligosaccharides is 2 to 250, more preferably 2 to 60.
Stodgy oligosaccharides be selected from it is following it is at least one, preferably at least two kinds：FOS (fructo-
Oligosaccharides), galactooligosaccharicomposition (galacto-oligosaccharides), glucose oligosaccharide (gluco-
Oligosaccharides), AOS (arabino-oligosaccharides), mannan-oligosaccharides (mannan-
Oligosaccharides), wood oligose (xylo-oligosaccharides), fucose (fuco-
Oligosaccharides), arabogalactan oligosaccharides (arabinogalacto-oligosaccharides), glucose sweet dew
Oligosaccharides (glucomanno-oligosaccharides), the galactomannan-oligosaccharide for including oligosaccharides and oligosaccharide
(galactomanno-oligosaccharides) sialic acid.It is preferred that the present composition includes FOS, galactooligosaccharicomposition
And/or galactoronic acid oligosaccharides, more preferably galactooligosaccharicomposition, most preferably beta galactose oligosaccharides.FOS group includes inulin, gala
Sugared oligosaccharides group includes TOS or beta galactose oligosaccharides, glucose oligosaccharide group include rough gentian-, black bent-and cyclodextrin-
Oligosaccharides and polydextrose, arabogalactan oligosaccharides group include gum arabic, and galactomannan-oligosaccharide group includes partial hydrolysis
Guar gum.
Preferably, stodgy oligosaccharides includes galactooligosaccharicomposition.Galactooligosaccharicomposition be preferably selected from beta galactose oligosaccharides,
LNT (LNT), Lacto-N-neo-tetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated
neo-LNT.In particularly preferred embodiments, stodgy oligosaccharides includes beta galactose oligosaccharides.As used herein in the present
Beta galactose oligosaccharides refer to by more than 50%, the widow that preferably greater than 65% galactose units based on monomer subunits are constituted
Sugar, the degree of polymerization (DP) is 2-20, wherein at least 50%, more preferably at least 75%, even more desirably at least 90% galactolipin list
Member is linked together by β-glycosidic bond, preferably β-Isosorbide-5-Nitrae glycosidic bond.Average DP is preferably 3 to 6.Glucose unit may be present in
The reducing end of the chain of galactose units.Beta galactose oligosaccharides is also known as TOS (TOS) sometimes.Beta galactose oligosaccharides
Suitable source beGOS (commercially available in Domo Ingredients, Netherlands).Other suitably come
Source is(Yakult)、(Nissin) and(Classado)。
In one embodiment, stodgy oligosaccharides includes FOS.FOS as used in the present invention refers to
The oligosaccharides being made up of the fructose units based on monomer subunits more than 50%, more than 65%, wherein at least 50%, more preferably extremely
Few 75%, even more desirably at least 90% fructose units are linked together by β-glycosidic bond, preferably β -2,1 glycosidic bonds.Really
Sugar unit may be present in the reducing end of the chain of fructose units.It is preferred that the DP of FOS or average DP be 2 to 250, more preferably 2 to
100th, even more preferably 10 to 60.FOS is few comprising levan, hydrolysis levan, inulin, hydrolytic inulin and the fruit of synthesis
Sugar.In one embodiment, stodgy oligosaccharides includes the short chain fructo-oligosaccharides that average degree of polymerization (DP) is 3 to 6, more preferably
Hydrolytic inulin or the FOS of synthesis.In one embodiment, it is preferred to which ground, stodgy oligosaccharides includes average DP more than 20
Long-chain FOS, such as(Beneo, Belgium).Preferably, composition includes short chain and long-chain FOS.
FOS suitable for composition is also easily commercially available, such as Orafti(Beneo, Belgium).
It is few that stodgy oligosaccharides used according to the invention preferably comprises oligosaccharide, more preferably galacturonic acid
Sugar.Term galactoronic acid oligosaccharides as used in the present invention refer to wherein be present at least 50% monosaccharide unit in oligosaccharides
For the oligosaccharides of galactolipin aldose.The galactoronic acid oligosaccharides used in the present invention are preferably by pectin, pectate and/or poly- gala
The degraded of uronic acid and prepare.It is preferred that the pectin degraded passes through fruit pectin and/or plant pectin, more preferably apple pectin, mandarin orange
Tangerine pectin and/or beet pectin, apple pectin pectin, citrus and/or the sweet tea even more preferably degraded by least one lyases
The hydrolysis and/or β-elimination of dish pectin and prepare.In preferred embodiments, at least one end of galactoronic acid oligosaccharides
Galacturonic acid units have double bond.Double bond effectively prevents attachment of the pathogen to enterocyte.It is preferred that terminal galactose
One of aldehydic acid unit includes C4-C5Double bond.Galactoronic acid oligosaccharides can be derivatization.Galactoronic acid oligosaccharides can be first
It is epoxide and/or amidated.In one embodiment, galactoronic acid oligosaccharides are characterised by that methoxylation degree exists
More than 20%, preferably more than 50%, even more preferably more than 70%.
Therefore, in one embodiment, the stodgy oligosaccharides in the method according to the invention or purposes is comprising extremely
Few beta galactose oligosaccharides.In one embodiment, the stodgy oligosaccharides in the method according to the invention or purposes is included
At least short chain fructo-oligosaccharides and/or long-chain FOS, preferably long-chain FOS.In one embodiment, according to the side of the present invention
Stodgy oligosaccharides in method or purposes includes at least oligosaccharide.In one embodiment, according to the side of the present invention
Stodgy oligosaccharides in method or purposes comprising at least beta galactose oligosaccharides and at least short chain fructo-oligosaccharides or long-chain FOS or
Both have concurrently.In one embodiment, the stodgy oligosaccharides in the method according to the invention or purposes comprising at least β-
Galactooligosaccharicomposition and at least oligosaccharide.In one embodiment, being difficult in the method according to the invention or purposes disappears
The oligosaccharides of change includes at least short chain fructo-oligosaccharides and oligosaccharide or long-chain FOS and oligosaccharide.In an embodiment
In, stodgy oligosaccharides in the method according to the invention or purposes comprising at least beta galactose oligosaccharides and short chain fructo-oligosaccharides with
And oligosaccharide or at least beta galactose oligosaccharides and long-chain FOS and oligosaccharide.
In preferred embodiments, the stodgy oligosaccharides in the method according to the invention or purposes comprising inulin and
The mixture of FOS.In preferred embodiments, the stodgy oligosaccharides bag in the method according to the invention or purposes
Mixture (being selected from short chain fructo-oligosaccharides and inulin, more preferably inulin) containing galactooligosaccharicomposition and FOS.
If using the mixture of two kinds of different stodgy oligosaccharides, the mixing of preferably galactose oligosaccharides and FOS
The weight ratio of thing, the preferably mixture of both different stodgy oligosaccharides is 20 to 0.05, more preferably 20 to 1.It is preferred that
It is 2-60's that stodgy oligosaccharides in the method according to the invention or purposes, which includes the galactooligosaccharicomposition and DP that DP is 2-10,
FOS.In one embodiment, stodgy oligosaccharides includes beta galactose oligosaccharides, FOS and pectin degradation product.
Beta galactose oligosaccharides: FOS: the weight of pectin degradation product is than being preferably (20-2): 1: (1-20), more preferably (12-7): 1:
(1-3)。
Preferably, with by 0.05 to 50g stodgy oligosaccharides, preferably 0.1 to 25g, preferably 0.5 to 15g, preferably 1 to
10g, the recipe of preferably 1 to 5g composition apply stodgy oligosaccharides to breast-feeding mothers.The method or purposes of the present invention is preferred
Including apply by 0.05 to 50g galactooligosaccharicomposition+FOS, preferably 0.1 to 25g, preferably 0.5 to 15g, preferably 1 to 10g, it is excellent
Select the recipe of 1 to 5g galactooligosaccharicomposition+FOS composition.The method or purposes of the present invention preferably includes to apply by 0.05 to 50g
Galactooligosaccharicomposition, preferably 0.1 to 25g, preferably 0.5 to 15g, preferably 1 to 10g, preferably 1 to the 5g galactooligosaccharicompositions food constituted
Spectrum.
The present invention method or purposes preferably include to apply 0.05 to 50g stodgy sugar daily, daily preferably 0.1 to
25g, preferably 0.5 to 15g, preferably 1 to 10g, preferably 1 to 5g.The method or purposes of the present invention preferably includes to apply 0.05 daily
To 50g galactooligosaccharicompositions+FOS, preferably 0.1 to 25g, preferably 0.5 to 15g, preferably 1 to 10g, preferably 1 to 5g galas daily
Sugared oligosaccharides+FOS.The method or purposes of the present invention preferably includes to apply 0.05 daily to 50g galactooligosaccharicompositions, daily preferably
0.1 to 25g, preferably 0.5 to 15g, preferably 1 to 10g, preferably 1 to 5g galactooligosaccharicompositions.
Nursing women
In the context of the present invention, ursing mother includes drawing breast milk and the breast milk drawn to infant feeding by bottle
Women.
The method according to the invention or purposes, the ursing mother to baby apply stodgy oligosaccharides.It is preferred that from baby
From that day of birth stodgy oligosaccharides is applied to ursing mother.Preferably last for applying stodgy oligosaccharides to ursing mother
Until that day of the complete stops lactation of mother.
Baby
The method or purposes of the present invention is good for one's health baby born after the normal gestation period.In preferred embodiments, it is of the invention
Method or purposes be beneficial to the baby that is prone to anxiety.
Composition
Stodgy oligosaccharides can be applied to women breast-feeding their children in the form of rod, capsule, tablet, liquid or pulvis.It is suitable
Locality, pulvis can before its intake with any kind of food or beverage blends.
Preferably, stodgy oligosaccharides is in the form of the nutritious supplementary pharmaceutical of women breast-feeding their children.In an embodiment
In, stodgy oligosaccharides is pulvis, and it is packaged in stodgy comprising 1-10g, more preferably 1.5-7g, most preferably 2-5g
In the sachet of oligosaccharides.
The present invention method or purposes in, preferably stodgy oligosaccharides with daily 0.5 to 50g, preferably daily 0.1 to
25g, preferably daily 0.5 to 15g, preferably daily 1 to 10g, preferably daily 1 to 5g, preferably daily 3 to 25g, preferably daily 6 to
12g amount is applied to women breast-feeding their children.Preferably, the daily dose is with daily a administration.Preferably, the daily dose is divided into 2
Or 3 or 4 parts, it eats 2 respectively daily, 3 or 4 times.
Using
According to the present invention, the anxiety for the baby that breast milk is obtained from the mother for having taken in stodgy oligosaccharides is reduced.
Herein and its in claim, verb "comprising" and its version are used for meaning bag with its non-limiting sense
The project behind the word is included, but is not precluded from the project that is not specifically mentioned.In addition, being carried by indefinite article " a " or " an "
And key element is not excluded for the possibility that more than one this key element is present, unless substantially required there is one and only one in context
This key element.Therefore, indefinite article " a " or " an " generally represent " at least one ".
Prebiotics in embodiment-nursing period dam (dam) diet reduces the anxiety of offspring
The postpartum diet intervention by short chain GOS and long-chain FOS is checked to anxiety sample in the Balb/cByJ mouse of health
The influence of behavior.
By Balb/cByJ mouse (Charles the River Laboratories, Maastricht, The of pregnancy
Netherlands) it is housed individually in the plastics cage containing standard pellet bed course and can freely obtains food and water.Balb/c is small
Mouse is known anti-social mouse, and it shows increased anxiety-like behavior compared to other Murine models.
Then 12h light/dark circulation (7AM-7PM) is carried out.The date of birth of young mouse is the 0th day postpartum (P0).From P0, n
=6 dam's feedings are rich in 3%scGOS/lcFOS diet, n=9 dam's feeding control diet (AIN93G).
In P21, male offspring wean is given.It is randomly formed every cage of two cages of the dam from feeding GOS/FOS diet
Five males, and it is randomly formed five males of every cage of two cages of the dam from feeding AIN93G diet.Come from addition, being formed
Six males of the cage of the dam of feeding control diet, these mouse are risen as interaction in social activity interaction test
Mouse.The dam's identical diet come from it is provided to offspring, n=10 male mice feeding 3%GOS/FOS drink is formed
N=16 male mice feeding AIN93G diet of food and total.
The measurement of the ultrasonic vocalization of separant induction
The painful sounding of ultrasonic wave of male offspring is measured in P10 to determine anxiety-like behavior.To have and wherein placed
The ultrasonic vocalization trial circle tubular article (UltraSound Advice, London, United Kingdom) of the lid of loudspeaker
With amplifier and with registration software (SonoTrack, MetrisB.V.；Hoofddorp, The Netherlands) computer
Connection.The aluminium bottom of cylindric thing and Julabo F12-ED heat cycles devices (Sigma-Aldrich；Zwijndrecht, The
Netherlands) connect to maintain the temperature at 19 DEG C.The young mouse of young mouse and dam and its littermate is separated and is placed on
Three minutes in cylindric thing, during this period, the measurement number of calls, average call time and average calling wavelength.In the examination
The young mouse of female affine littermate is housed in identical room during testing.
Statistical method
Examined using double tail Student ' the s t- of non-matching and statistical analysis is carried out the difference group.When not being normal state point
During cloth, natural logrithm change data is used before statistical analysis.Data use Graph Pad Prism, and the 6th edition is shown as flat
Mean value ± SEM.As P ＜ 0.05, it is believed that result has significance,statistical.
As a result
The reduction of ultrasonic vocalization is shown by the young mouse of dam's lactation of feeding scGOS/lcFOS diet
In P10, measure the painful sounding of ultrasonic wave to evaluate anxiety-like behavior.Male juvenile mouse is separated 3 with dam respectively
Minute, during this period, determine the UV numbers of calls, average call time and average calling frequency.Compareed compared to by feeding
The mouse of dam's lactation of diet, is significantly dropped by the number of calls in the young mouse of dam's lactation of feeding scGOS/lcFOS diet
Low (P=0.040).
In addition, thering is trend to show compared to control-animal, in the young mouse of dam's lactation of feeding scGOS/lcFOS diet
The lasting average time reduction (P=0.065) of calling.
Obvious difference is cannot make out in the frequency (Hz) of the average call sent by different young mouse.
As a result it is summarized in table 1
Table 1：The reduction of ultrasonic vocalization is shown by the young mouse of dam's lactation of feeding scGOS/lcFOS diet
Control diet：AIN93G
These results show that the prebiotics diet of nursing period reduces the anxiety of offspring.
Claims (10)
1. purposes of the stodgy oligosaccharides in the composition for preparing the anxiety for being used for reducing breast feeding babies, wherein will bag
Composition containing stodgy oligosaccharides is applied to the ursing mother of baby.
2. purposes according to claim 1, wherein the stodgy oligosaccharides includes galactooligosaccharicomposition, its average degree of polymerization is excellent
Elect 3-6 as.
3. according to the purposes of any one of preceding claims, wherein the stodgy oligosaccharides includes FOS, it is averaged
Polymer degree is preferably more than 10, and preferably more than 20.
4. according to the purposes of any one of preceding claims, wherein the stodgy oligosaccharides includes galactooligosaccharicomposition and fruit
Oligosaccharides, their weight ratio preferably 20: 0.5.
5. according to the purposes of any one of preceding claims, wherein the baby is prone to anxiety.
6. according to the purposes of any one of preceding claims, wherein the composition is the form of nutritious supplementary pharmaceutical.
7. according to the purposes of any one of preceding claims, wherein the stodgy oligosaccharides is from that day of baby due
It is applied to ursing mother.
8. according to the purposes of any one of preceding claims, wherein persistently applying the stodgy oligosaccharides until mother is complete
That day of full stops lactation.
9. according to the purposes of any one of preceding claims, wherein the stodgy oligosaccharides is applied with daily 1 to 12g amount
For ursing mother.
10. a kind of be used to reduce the non-medical method of the anxiety of breast feeding babies, it to the ursing mother of baby by applying
Stodgy oligosaccharides and carry out.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14184828.3 | 2014-09-15 | ||
| EP14184828 | 2014-09-15 | ||
| PCT/NL2015/050636 WO2016043583A1 (en) | 2014-09-15 | 2015-09-15 | Reducing anxiety in progeny |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107106582A true CN107106582A (en) | 2017-08-29 |
Family
ID=51539200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580061897.1A Pending CN107106582A (en) | 2014-09-15 | 2015-09-15 | Reduce offspring's anxiety |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3193886A1 (en) |
| CN (1) | CN107106582A (en) |
| WO (1) | WO2016043583A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114761024A (en) * | 2019-11-29 | 2022-07-15 | 格礼卡姆股份公司 | HMO mixture for improving microbiota of pregnant women |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013117235A1 (en) * | 2012-02-10 | 2013-08-15 | N.V. Nutricia | Maternal supplement to enhance immune system of an infant |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ571158A (en) * | 2006-03-10 | 2011-08-26 | Nutricia Nv | Use of non-digestible saccharides administered to a pregnant woman for giving an infant the best start after birth |
| EP2127661A1 (en) * | 2008-05-27 | 2009-12-02 | Nestec S.A. | Probiotics to improve gut microbiotica |
| WO2013126015A1 (en) * | 2012-02-23 | 2013-08-29 | N. V. Nutricia | Composition comprising non- digestible oligosaccharides |
| PL2914136T3 (en) * | 2012-11-02 | 2021-11-29 | N.V. Nutricia | Synbiotics combination for brain improvement |
-
2015
- 2015-09-15 EP EP15794326.7A patent/EP3193886A1/en not_active Withdrawn
- 2015-09-15 CN CN201580061897.1A patent/CN107106582A/en active Pending
- 2015-09-15 WO PCT/NL2015/050636 patent/WO2016043583A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013117235A1 (en) * | 2012-02-10 | 2013-08-15 | N.V. Nutricia | Maternal supplement to enhance immune system of an infant |
Non-Patent Citations (2)
| Title |
|---|
| 张丽君: "情绪与肠道微生物", 《中国食品报》 * |
| 滕超等: "功能性寡糖研究及其在食品中的应用进展", 《食品安全质量检测学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114761024A (en) * | 2019-11-29 | 2022-07-15 | 格礼卡姆股份公司 | HMO mixture for improving microbiota of pregnant women |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3193886A1 (en) | 2017-07-26 |
| WO2016043583A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ruemmele | Role of diet in inflammatory bowel disease | |
| Lee et al. | Diet in the pathogenesis and treatment of inflammatory bowel diseases | |
| Myles | Fast food fever: reviewing the impacts of the Western diet on immunity | |
| CN101766228B (en) | Iimmune stimulatory infant nutrition | |
| RU2358474C2 (en) | Prebiotic compositions | |
| CN101094687B (en) | Nutritional composition comprising immunoglobulin and oligosaccharides | |
| Dsilna et al. | Continuous feeding promotes gastrointestinal tolerance and growth in very low birth weight infants | |
| EP1957084B1 (en) | Composition containing oligosaccharides for the treatment / prevention of fever and febrile seizures | |
| JP2005513079A (en) | Soft drink replacement | |
| CN111050851A (en) | Human milk oligosaccharides for improved immune adaptability | |
| JP2009167172A (en) | Composition for controlling intestinal disorder and/or improving bowel movement | |
| TW201332555A (en) | Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring | |
| CN106604651A (en) | Nutritional composition for treating or preventing pregnancy-related disorders | |
| Sharma et al. | Miraculous health benefits of prebiotics | |
| EP4048283A1 (en) | Compositions comprising 2'-fucosyllactose to prevent asthma | |
| CN107106582A (en) | Reduce offspring's anxiety | |
| Bogdanova et al. | P19 Epigenetic factors of atopic phenotype formation in infants, born from mothers with bronchial asthma | |
| Bocquet | Diversification alimentaire | |
| RU2716214C2 (en) | Composition for brain improvement | |
| WO2011136634A1 (en) | Preventing salmonella infection induced weight loss | |
| CN104168778B (en) | Strengthen the parent supplement of infant immunization system | |
| JP6902797B2 (en) | Nutritional composition for diarrhea prevention | |
| EP3888661A1 (en) | Compositions comprising 2 -fucosyllactose to prevent viral infections | |
| CN101959522B (en) | Ketone accumulation inhibitor | |
| JP4894044B2 (en) | Intestinal environment improving composition, sweetening composition and functional food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170829 |